Scarica l'app Stockscreener
11.63
0.95%
0.11
Dopo l'orario di chiusura:
11.61
-0.02
-0.17%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals Holding Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Millennium group reports 890,366 shares (5.6%) in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals director Taylor buys $14,928 in stock By Investing.com - Investing.com South Africa
Insider Buying: Carolyn Taylor Acquires Shares of Tonix Pharmace - GuruFocus
Director Carolyn Taylor buys Tonix Pharmaceuticals (TNXP) shares in open market - Stock Titan
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate - Yahoo Finance
Tonix Pharmaceuticals Holding Corp (TNXP) Stock Price, Quote, News & History - Benzinga
Tonix Pharmaceuticals Holding Corp. Trade Ideas — TRADEGATE:TPM0 - TradingView
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 - marketscreener.com
(TNXP) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tonix CEO Seth Lederman buys $58,949 in company stock By Investing.com - Investing.com Canada
Insider Buying: Richard Stillwell Acquires Shares of Tonix Pharm - GuruFocus
Tonix Pharmaceuticals director Stillwell buys $58,250 in shares By Investing.com - Investing.com Canada
Tonix CEO Seth Lederman buys $58,949 in company stock - Investing.com UK
Tonix Pharmaceuticals director Stillwell buys $58,250 in shares - Investing.com
[Form 4] Tonix Pharmaceuticals Holding Corp. Insider Trading Activity - Stock Titan
Tonix (NASDAQ: TNXP) CEO Lederman acquires 5,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals (TNXP) Expands Tonmya Coverage to 17 Milli - GuruFocus
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Blue Owl Capital (OBDC) Regains Ground: Modest Gain Signals Stability Near Key LevelsBearish Sentiment - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharmaceuticals Expands TONMYA® Fibromyalgia Coverage to 52 Million Lives with Second Major GPO Agreement - Minichart
Tonix Pharmaceuticals stock gains on expanded TONMYA coverage By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals stock gains on expanded TONMYA coverage - Investing.com
Tonix expands commercial coverage for fibromyalgia drug TONMYA - Investing.com UK
Tonix expands commercial coverage for fibromyalgia drug TONMYA By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals secures GPO coverage for TONMYA, expanding commercial access to ~52M U.S. lives - TradingView
TONMYA coverage reaches 52M U.S. commercial lives under GPO deals (TNXP) - Stock Titan
First new fibromyalgia medicine in over 15 years now covered for 52M people - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
BTS ARIRANG Exhibition at ARTE Museum Poised to Drive Las Vegas Tourism RevenueUpward Estimate Revision - The Legal Advocate
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
Tonix presents data on opioid use in fibromyalgia patients By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Unveils Findings on Opioid Use in F - GuruFocus
Tonix presents data on opioid use in fibromyalgia patients - Investing.com UK
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - GlobeNewswire
Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants - GlobeNewswire Inc.
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tonix Pharmaceuticals (TNXP) Publishes Positive Phase 1 Study Re - GuruFocus
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):